NCT03847181View on ClinicalTrials.gov

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

45,164

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban at a dose of 15 or 20 mg once daily

DRUG

Apixaban (Eliquis)

Apixaban at a dose of 2.5 or 5 mg twice daily

DRUG

Warfarin

Warfarin dose as prescribed by medical practitioner

Trial Locations (1)

Unknown

Many facilities, Many Sites

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Bayer

INDUSTRY

NCT03847181 - Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice | Biotech Hunter | Biotech Hunter